Zealand Pharma AS (fra:22Z) Share Price

Company Profile

Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNK
T: +45 88773600
E: [email protected]
https://www.zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544

Recommended

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Brian Colello, CPA | 23 July 2026

A closer look at the stocks and ETFs that captured Aussie investors’ attention in FY26.

Tyger Fitzpatrick | 23 July 2026

Where value remains in Australian banks.

Tyger Fitzpatrick | 23 July 2026

Index	Last price	Change	% Change
All Ordinaries	9,018.10	41.40	-0.46%
CAC 40	8,344.60	93.29	-1.11%
DAX 40	25,001.59	153.82	-0.61%
Dow JONES (US)	52,218.58	6.06	-0.01%
FTSE 100	10,700.50	16.47	-0.15%
HKSE	25,210.81	318.15	1.28%
NASDAQ	25,690.90	146.30	-0.57%
Nikkei 225	66,422.60	307.00	0.46%
NZX 50 Index	13,795.31	32.13	0.23%
S&P 500	7,498.96	10.24	-0.14%
S&P/ASX 200	8,839.00	38.60	-0.43%
SSE Composite Index	3,876.78	9.74	0.25%